1,383 reports of this reaction
3.3% of all CALCITRIOL CAPSULES 0.25 MCG reports
#1 most reported adverse reaction
NAUSEA is the #1 most commonly reported adverse reaction for CALCITRIOL CAPSULES 0.25 MCG, manufactured by Strides Pharma Science Limited. There are 1,383 FDA adverse event reports linking CALCITRIOL CAPSULES 0.25 MCG to NAUSEA. This represents approximately 3.3% of all 42,159 adverse event reports for this drug.
Patients taking CALCITRIOL CAPSULES 0.25 MCG who experience nausea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NAUSEA is moderately reported among CALCITRIOL CAPSULES 0.25 MCG users, representing a notable but not dominant share of adverse events.
In addition to nausea, the following adverse reactions have been reported for CALCITRIOL CAPSULES 0.25 MCG:
The following drugs have also been linked to nausea in FDA adverse event reports:
NAUSEA has been reported as an adverse event in 1,383 FDA reports for CALCITRIOL CAPSULES 0.25 MCG. This does not prove causation, but indicates an association observed in post-market surveillance data.
NAUSEA accounts for approximately 3.3% of all adverse event reports for CALCITRIOL CAPSULES 0.25 MCG, making it one of the most commonly reported side effect.
If you experience nausea while taking CALCITRIOL CAPSULES 0.25 MCG, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.